Amgen, Inc.
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1980-01-01
- Employees
- 26.7K
- Market Cap
- $175.6B
- Website
- http://www.amgen.com
AMG 714 Expanded Access Program
- Conditions
- First Posted Date
- 2018-02-20
- Last Posted Date
- 2024-05-10
- Lead Sponsor
- Amgen
- Registration Number
- NCT03439475
Safety and Efficacy of Evolocumab in Addition to Optimal Stable Background Statin Therapy in Chinese Participants With Primary Hypercholesterolemia and Mixed Dyslipidemia
- Conditions
- Interventions
- First Posted Date
- 2018-02-15
- Last Posted Date
- 2023-03-27
- Lead Sponsor
- Amgen
- Target Recruit Count
- 259
- Registration Number
- NCT03433755
- Locations
- 🇨🇳
Sun Yat-sen Memorial Hospital Sun Yat-sen University, Guangzhou, Guangdong, China
🇨🇳The Third Xiangya Hospital of Central South University, Changsha, Hunan, China
🇨🇳Affiliated Hospital of Jiangsu University, Zhenjiang, Jiangsu, China
A Comparison of Subject-administered Romosozumab With Healthcare Provider-administered Romosozumab for Osteoporosis
- Conditions
- Interventions
- First Posted Date
- 2018-02-14
- Last Posted Date
- 2020-11-23
- Lead Sponsor
- Amgen
- Target Recruit Count
- 283
- Registration Number
- NCT03432533
- Locations
- 🇬🇧
Research Site, Romford, United Kingdom
Safety and Efficacy of Efavaleukin Alfa in Subjects With Active Rheumatoid Arthritis
- First Posted Date
- 2018-01-25
- Last Posted Date
- 2021-06-22
- Lead Sponsor
- Amgen
- Target Recruit Count
- 36
- Registration Number
- NCT03410056
- Locations
- 🇪🇸
Research Site, A Coruña, Galicia, Spain
A Phase 1 Study Evaluating the Safety, Tolerability and Efficacy of AMG 119 in Subjects With RR SCLC
- First Posted Date
- 2018-01-05
- Last Posted Date
- 2023-09-15
- Lead Sponsor
- Amgen
- Target Recruit Count
- 6
- Registration Number
- NCT03392064
- Locations
- 🇺🇸
Research Site, Houston, Texas, United States
Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects With Lymphoma.
- Conditions
- Interventions
- First Posted Date
- 2017-11-17
- Last Posted Date
- 2018-01-19
- Lead Sponsor
- Amgen
- Registration Number
- NCT03343847
Study of Glycerol Phenylbutyrate & Sodium Phenylbutyrate in Phenylbutyrate Naïve Patients With Urea Cycle Disorders (UCDs)
- First Posted Date
- 2017-11-07
- Last Posted Date
- 2024-07-01
- Lead Sponsor
- Amgen
- Target Recruit Count
- 16
- Registration Number
- NCT03335488
- Locations
- 🇺🇸
Mount Sinai School of Medicine, New York, New York, United States
🇪🇸Hospital Materno-Infantil (HRU Carlos Haya), Málaga, Andalucia, Spain
🇮🇹Bambino Gesù Children's Research Hospital, Rome, Italy
A Study of the Efficacy and Safety of Apremilast (CC-10004) in Subjects With Moderate to Severe Plaque Psoriasis of the Scalp
- First Posted Date
- 2017-04-21
- Last Posted Date
- 2020-05-13
- Lead Sponsor
- Amgen
- Target Recruit Count
- 303
- Registration Number
- NCT03123471
- Locations
- 🇺🇸
Dermatologic Surgery Specialists, P.C., Macon, Georgia, United States
🇺🇸University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States
🇺🇸Renstar Medical Research, Ocala, Florida, United States
Observational Study of Blinatumomab
- Conditions
- First Posted Date
- 2017-04-18
- Last Posted Date
- 2024-03-29
- Lead Sponsor
- Amgen
- Target Recruit Count
- 279
- Registration Number
- NCT03117621
- Locations
- 🇵🇱
Szpital Specjalistyczny imienia Ludwika Rydygiera w Krakowie Sp zoo, Kraków, Poland
🇵🇹Centro Hospitalar de Lisboa Central, EPE - Hospital de Santo Antonio dos Capuchos, Lisboa, Portugal
🇨🇭Universitaetsspital Basel, Basel, Switzerland
Evolocumab Pregnancy Exposure Registry
- First Posted Date
- 2016-11-08
- Last Posted Date
- 2020-12-17
- Lead Sponsor
- Amgen
- Target Recruit Count
- 140
- Registration Number
- NCT02957604